Skip to content

Midlines and Thrombophlebitis

Randomized Comparative Evaluation of Midline Catheters for Thrombophlebitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03725293
Enrollment
212
Registered
2018-10-31
Start date
2019-01-14
Completion date
2020-11-26
Last updated
2022-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter Complications, Catheter Infection, Catheter Thrombosis

Keywords

thrombosis, superficial venous thrombosis, deep venous thrombosis, line related infection, catheter survival

Brief summary

Peripherally inserted central catheters (PICCs) are central catheters that are placed via peripheral vein under ultrasound guidance and may be used for patients with difficult venous access for long-term central or peripheral infusion therapies as well as central venous pressure monitoring in a critical care setting. Although PICCs provide a great option for some patients, these catheters have known complications including catheter-related bloodstream infection, catheter-related venous thrombosis or clotting, malfunction, and high cost. Midline catheters represent a potentially attractive alternative to PICCs for peripheral infusions. As midlines have increased in popularity and new midlines have been introduced into the market, it is necessary to better understand complication profiles of various midline catheters, as it is likely that all catheters are not created equal. Specifically, the incidence of symptomatic catheter-related thrombosis is of interest. Some midline catheters are coated to provide protection against catheter-related venous thrombosis and/or catheter-related bloodstream infection. The theoretical benefit(s) of these catheters need further validation in human subjects.

Detailed description

Study Design The investigators propose a prospective single-site, parallel, two-arm, randomized investigation to assess catheter-related symptomatic upper extremity venous thrombosis (CR-UEVT), catheter-related bloodstream infection, and functionality of two single lumen midline catheters: AngioDynamics BioFlo 4 F and Teleflex Arrowg+ard Blue Advance 4.5 F. Research staff of Beaumont Health Institute will allocate two midline catheters to eligible participants according to a pre-generated randomized list at a 1:1 ratio in block randomization to AngioDynamics BioFlo or Tele-flex Arrowg+ard Blue Advanced midline catheters. Participant enrollment will take place from November 2018 until recruitment of 250 participants, 125 in each group, is complete. Demographic and health-related information will be obtained from electronic medical records during enrolled period at William Beaumont Hospital. Practitioner Participation/Training Advanced Practice Providers within the bedside PICC/Midline service at the Royal Oak campus are eligible to place catheters for this study. All investigators are credentialed in placing PICCs and midlines by institutional policy and have greater than one year of experience in these procedures. Initial Assessment Post-cannulation and post securement, functionality is confirmed with blood sampling (10 cc) and flush without resistance. The research team also will document practitioner details, the vascular access device (VAD) used, the time of VAD placement, number of attempts, need for a rescue inserter, the vein that was cannulated, depth and diameter of the vein, and the indication for VAD placement. An attempt is defined as each time the needle punctures the skin. Data will be collected from the electronic medical record and includes: age, gender, body mass index (BMI), vital signs, relevant past medical history. Indication for catheter placement will also be recorded. Follow-up Assessment Investigators will perform a follow-up assessment on all catheters within 24 hours of insertion and then daily for the life of the VAD. At each follow-up interval, the researcher will document the time of evaluation and assessment of functionality as well as review the patient chart for signs and symptoms of catheter-related bloodstream infection. If the catheter was identified to have failed during follow-up assessment the date and time of failure and the reason for failure will be documented. For all failed catheters, re-insertion attempt data will be tracked through the medical record. Superficial venous thrombosis (SVT) and deep venous thrombosis (DVT) rates will be calculated based on upper extremity proven diagnosis of SVT and/or DVT in symptomatic cases. Radiology interpretations will be reviewed for findings consistent with CR-UEVT. Infection rate will be tracked using confirmed catheter-related blood stream infection data from the surveillance team within the epidemiology department. The team utilizes the CDC definition of laboratory-confirmed blood-stream infection (LCBSI). The medication administration record will be queried for all medications given through each catheter.

Interventions

DEVICEAngiodynamics BioFlo Midline Catheter

Placement of Angiodynamics BioFlo Midline Catheter.

DEVICETeleflex Arrowg+ard Blue Advanced Midline Catheter

Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.

Sponsors

Teleflex
CollaboratorINDUSTRY
Corewell Health East
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective single-site, parallel, two-arm, randomized investigation

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All inpatients 18 years of age and older * Inpatients that require midline catheter placement by the bedside vascular access team

Exclusion criteria

* Do not meet inclusion criteria * Multiple lumens required * Alternative diameter of catheter used * If already enrolled once prior * Withdraw voluntarily from the study * Actively (within 24 hours) taking a therapeutic dose of an anticoagulant (heparin, low molecular weight heparin, enoxaparin, rivaroxaban, apixaban, dabigatran, edoxaban, warfarin, arixtra, factor Xa inhibitors) * Receiving a midline catheter for anticoagulant therapy

Design outcomes

Primary

MeasureTime frameDescription
Upper Extremity CR-UEVT30 days post line insertionNumber of participants with proven sonographic diagnosis of DVT and/or SVT

Secondary

MeasureTime frameDescription
Line Related Infection30 days post line insertionNumber of participants with catheter related laboratory confirmed bloodstream infection per Centers for Disease Control (CDC) guidelines

Countries

United States

Participant flow

Participants by arm

ArmCount
Angiodynamics BioFlo Midline Catheter
Placement of clinically indicated Angiodynamics BioFlo midline catheter. Angiodynamics BioFlo Midline Catheter: Placement of Angiodynamics BioFlo Midline Catheter.
94
Teleflex Arrowg+Ard Blue Advanced Midline Catheter
Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter Teleflex Arrowg+ard Blue Advanced Midline Catheter: Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
97
Total191

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall Studyalternative vascular access needs12
Overall StudyPhysician Decision96
Overall Studyvenous anatomy screen failures21

Baseline characteristics

CharacteristicTeleflex Arrowg+Ard Blue Advanced Midline CatheterTotalAngiodynamics BioFlo Midline Catheter
Age, Continuous59.5 years
STANDARD_DEVIATION 17.1
60.2 years
STANDARD_DEVIATION 16.7
60.29 years
STANDARD_DEVIATION 16.3
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
97 Participants191 Participants94 Participants
Sex: Female, Male
Female
60 Participants114 Participants54 Participants
Sex: Female, Male
Male
37 Participants77 Participants40 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 940 / 97
other
Total, other adverse events
22 / 9420 / 97
serious
Total, serious adverse events
1 / 940 / 97

Outcome results

Primary

Upper Extremity CR-UEVT

Number of participants with proven sonographic diagnosis of DVT and/or SVT

Time frame: 30 days post line insertion

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Angiodynamics BioFlo Midline CatheterUpper Extremity CR-UEVT7 Participants
Teleflex Arrowg+Ard Blue Advanced Midline CatheterUpper Extremity CR-UEVT11 Participants
Secondary

Line Related Infection

Number of participants with catheter related laboratory confirmed bloodstream infection per Centers for Disease Control (CDC) guidelines

Time frame: 30 days post line insertion

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Angiodynamics BioFlo Midline CatheterLine Related Infection0 Participants
Teleflex Arrowg+Ard Blue Advanced Midline CatheterLine Related Infection0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026